A phase 1 study of Olaparib, a poly ADP-ribose polymerase-1 (PARP) inhibitor, in combination with metronomic cyclophosphamide in patients with metastatic BRCA-associated cancer, triple negative breast cancer or serous ovarian cancer (ANZ 1103 SOLACE)

* Dataset for 32 patients with metastatic triple negative breast cancer or metastatic breast cancer and documented BRCA1or BRCA2 mutation (9 breast cancer patients) or high grade serous epithelial ovarian cancer with or without documented BRCA1 or BRCA2 mutation (23 ovarian cancer patients). * Determine maximum tolerated dose of olaparib in combination with metronomic oral cyclophosphamide for maximum of 8 cycles of treatment (1 cycle = 21 days) * Response rate, progression free survival, overall survival data.